Zhihua Li

Dr. Zhihua Li


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
ZLZhihua Li
Zhihua Li
PHPing-Hua Hu
Ping-Hua Hu
JTJian-Hong Tu
Jian-Hong Tu
NYNi-Si Yu
Ni-Si Yu
Luminal B breast cancer: patterns of recurrence and clinical outcome

6 November 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
ZLZhihua Li
Zhihua Li
XWXueling Weng
Xueling Weng
QXQiu-Yun Xiong
Qiu-Yun Xiong
JTJian-Hong Tu
Jian-Hong Tu
AXAn Xiao
An Xiao
YCYa-Li Cao
Ya-Li Cao
MiR-34a expression in human breast cancer is associated with drug resistance miR-34a expression in human breast cancer is associated with drug resistance

6 March 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
ZLZhihua Li
Zhihua Li
QXQiu-Yun Xiong
Qiu-Yun Xiong
LXLiang Xu
Liang Xu
PDPeng Duan
Peng Duan
QYQianwen Ou Yang
Qianwen Ou Yang
JTJian-Hong Tu
Jian-Hong Tu
MiR-29a regulated ER-positive breast cancer cell growth and invasion and is involved in the insulin signaling pathway miR-29a regulated ER-positive breast cancer cell growth and invasion and is involved in the insulin signaling pathway

17 May 2013 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
ZLZhihua Li
Zhihua Li
QXQiu-Yun Xiong
Qiu-Yun Xiong
JTJian-Hong Tu
Jian-Hong Tu
YGYu Gong
Yu Gong
WQWei Qiu
Wei Qiu
WCWei-Qi Cui
Wei-Qi Cui

1 January 2018
Verified
Journal Article
Closed access
ZLZhihua Li
Zhihua Li
LXLiang Xu
Liang Xu
YLYong Liu
Yong Liu
SFShaokun Fu
Shaokun Fu
JTJianhong Tu
Jianhong Tu
QXQiuyun Xiong
Qiuyun Xiong

6 July 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
QJQihua Jiang
Qihua Jiang
HHHai Hu
Hai Hu
JLJing Liao
Jing Liao
ZLZhihua Li
Zhihua Li
JTJunTao Tan
JunTao Tan
To establish and validate a predictive model for breast cancer-related lymphedema (BCRL) among Chinese patients to facilitate individualized risk assessment. We retrospectively analyzed data from breast cancer patients treated at a major single-center breast hospital in China. From 2020 to 2022, we identified risk factors for BCRL through logistic regression and developed and validated a nomogram using R software (version 4.1.2). Model validation was achieved through the application of receiver operating characteristic curve (ROC), a calibration plot, and decision curve analysis (DCA), with further evaluated by internal validation. Among 1485 patients analyzed, 360 developed lymphedema (24.2%). The nomogram incorporated body mass index, operative time, lymph node count, axillary dissection level, surgical site infection, and radiotherapy as predictors. The AUCs for training (N = 1038) and validation (N = 447) cohorts were 0.779 and 0.724, respectively, indicating good discriminative ability. Calibration and decision curve analysis confirmed the model’s clinical utility. Our nomogram provides an accurate tool for predicting BCRL risk, with potential to enhance personalized management in breast cancer survivors. Further prospective validation across multiple centers is warranted.